Patent ID: 8563254

Claim:
A method of assessing the efficacy of a treatment regimen for treating melanoma or gastric cancer in a subject, wherein the treatment regimen comprises administration of Hsp90 inhibitor NVP-AUY922, the method comprising: a) contacting a first tumor sample obtained from said subject prior to administering NVP-AUY922 to the subject with an anti-IL-8 antibody to detect IL-8 protein levels; b) contacting a second tumor sample obtained from the same subject following administration of NVP-AUY922 with an anti-IL-8 antibody to detect IL-8 protein levels; and c) comparing the IL-8 protein levels from the first and second tumor samples, wherein a 40-70% decrease in the level of IL-8 detected in the second tumor sample relative to the level of IL-8 detected in the first tumor sample is an indication that the treatment regimen is efficacious for treating melanoma or gastric cancer in the subject.